RESUMEN
IgA vasculitis is a form of cutaneous small-vessel leukocytoclastic vasculitis (LCV) that has various triggers, including anti-tumor necrosis factor (TNF) α therapy. As the use of more targeted biologic therapies such as the IL-17 inhibitor secukinumab increases, so do reports of associated adverse events. Herein, we describe an uncommon case of IgA vasculitis in a man undergoing biologic therapy with adalimumab and secukinumab for psoriasis with recurrent cutaneous methicillin-resistant Staphylococcus aureus (MRSA) colonization. A review of the current literature also is provided.
Asunto(s)
Vasculitis por IgA , Staphylococcus aureus Resistente a Meticilina , Psoriasis , Vasculitis Leucocitoclástica Cutánea , Masculino , Humanos , Psoriasis/tratamiento farmacológico , Terapia Biológica , Adalimumab/uso terapéutico , Vasculitis Leucocitoclástica Cutánea/tratamiento farmacológicoRESUMEN
An 88-year-old woman presented with an 8-year history of a slowly enlarging growth on the suprapubic area. A shave excision of this lesion demonstrated fibroepithelioma of Pinkus (FEP). Fibroepithelioma of Pinkus is an indolent growing tumor that traditionally has been classified as a variant of the basal cell carcinoma. More recent evidence favors the classification of FEP as a variant of trichoblastoma. In this case report, we identified a large FEP with benign histologic features suggestive of a follicular origin as demonstrated in part by CK 20 staining and the presence of scattered Merkel cells within the tumor. The pathogenesis of FEP remains enigmatic, and the genetic basis has yet to be fully elucidated. Complete surgical resection is considered curative.